Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Penumbra reports robust Q2 earnings, eyes growth amidst challenges

Penumbra's Q2 2024 earnings call showcased strong financial performance, operational efficiency, and a commitment to innovation and market access initiatives.
While facing challenges in revenue guidance reduction and competitive dynamics, the company's strengths in product performance and growth prospects position it well for the future.
Opportunities exist in leveraging innovation, addressing market challenges, and optimizing margins to drive sustained growth and competitiveness in the industry.

Penumbra reports strong Q3 earnings, eyes global blood clot market

Penumbra's Q3 2024 earnings call showcased robust financial performance, driven by revenue growth and margin expansion. The company's innovative technologies and regulatory milestones position it for future success in the blood clot treatment market. While facing challenges in sustaining growth and navigating market dynamics, Penumbra has opportunities to capitalize on its strengths and drive global transformation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Penumbra Inc (NYSE: PEN) announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter met the primary endpoint. As part of the Indigo Aspiration System, the Indigo CAT RX Aspiration Catheters and Indigo Separator 4 are indicated to remove fresh, soft emboli and thrombi from vessels in the coronary and peripheral vasculature.

Penumbra's Thrombectomy System Shows Safety, Clinical Benefit

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #mechanicalthrombectomy--CHEETAH study demonstrates safety and performance of continuous aspiration thrombectomy for coronary blood clots with Penumbra's Indigo System CAT RX.

New Data Demonstrates Safety and Performance of Continuous Aspiration Thrombectomy with Penumbra's Indigo® System CAT™ RX Catheter in High-Risk Patients with Acute Coronary Syndrome

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q3 2021 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of -14.29% and 4.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Lags Q3 Earnings Estimates

ALAMEDA, Calif., Nov. 3, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the third quarter ended September 30, 2021.

Penumbra, Inc. Reports Third Quarter 2021 Financial Results

ALAMEDA, Calif., Oct. 6, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the third quarter 2021 after market close on Wednesday, November 3, 2021 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules Third Quarter 2021 Earnings Release and Conference Call for November 3, 2021

NEW YORK, Sept. 22, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE: PEN) resulting from allegations that Penumbra may have issued materially misleading business information to the investing public.

PEN INVESTOR NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Penumbra, Inc. Investors with Losses to Inquire About Class Action Investigation - PEN

New York, New York--(Newsfile Corp. - September 21, 2021) -  Pomerantz LLP is investigating claims on behalf of investors of Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Penumbra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Penumbra, Inc. - PEN

ALAMEDA, Calif., Aug. 31, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021.

Penumbra, Inc. to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE:PEN) resulting from allegations that Penumbra may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Penumbra securities including options, between July 22, 2019 and December 15, 2020, and sold those securities for a loss you may be entitled to compensa

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Penumbra, Inc. Investors With Losses to Inquire About Class Action Investigation – PEN

ALAMEDA, Calif., Aug. 26, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 2021 Wells Fargo Virtual Healthcare Conference on Thursday, September 9, 2021.

Penumbra, Inc. to Present at the 2021 Wells Fargo Virtual Healthcare Conference

Penumbra Inc (NYSE: PEN) reported Q2 sales of $184.3 million, an increase of 75.3% Y/Y, or 72.7% on a constant currency basis, beating the consensus of $170.76 million. Revenue from sales of vascular products grew to $100.7 million, +117.6%, or 115.8% on a constant currency basis.

Penumbra Q2 Earnings Beat Estimates; Raises FY21 Sales Outlook

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #REALsystem--Penumbra is introducing the REAL® Immersive System i-Series™ designed for a broad range of care providers and mental health professionals.

Penumbra Introduces REAL® i-Series™, Expanding REAL Immersive System to Support Broad Range of Care Providers and Mental Health Professionals

Penumbra, Inc.'s (PEN) CEO Adam Elsesser on Q2 2021 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of 10.53% and 7.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Tops Q2 Earnings and Revenue Estimates

ALAMEDA, Calif., Aug. 9, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2021.

Penumbra, Inc. Reports Second Quarter 2021 Financial Results

ALAMEDA, Calif., July 28, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021.

Penumbra, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference

Penumbra has made a full recovery from lows of December 2020 as the company regains steam on the charts. Nothing changed fundamentally after the catheter recall, however the market punished PEN shares immediately afterwards.

Penumbra: Short Thesis Did Not Hold, Core Business Remains Strong

ALAMEDA, Calif., July 12, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2021 after market close on Monday, August 9, 2021 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules Second Quarter 2021 Earnings Release and Conference Call for August 9, 2021

Penumbra (PEN) to initiate commercialization of RED 62 Reperfusion Catheter post FDA clearance.

Penumbra (PEN) Gets FDA Nod for RED 62, Grows Thrombectomy Line

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #mechanicalthrombectomy--Penumbra has announced U.S. Food and Drug Administration (FDA) 510(k) clearance and commercial availability of the RED™ 62 Reperfusion Catheter.

Penumbra Receives FDA Clearance for RED 62 Reperfusion Catheter, Enabling Physicians to Address Broad Range of Stroke Patients

ALAMEDA, Calif., May 18, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair 41st Annual Growth Stock Virtual Conference on Tuesday, June 1, 2021.

Penumbra, Inc. to Present at the William Blair 41st Annual Growth Stock Virtual Conference

Penumbra (PEN) delivered earnings and revenue surprises of 145.45% and 10.41%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Q1 Earnings and Revenues Surpass Estimates

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q1 2021 Results - Earnings Call Transcript

Shares of Penumbra (NYSE:PEN) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 0.00% over the past year to $0.27, which beat the estimate of $0.09.

News for Penumbra Stock (PEN)